Skip to main content
Log in

Multidrug resistance in cancer chemotherapy

  • Review
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Resistance to chemotherapy is the single most important reason for treatment failure in cancer patients. Over the past 15 years, we have gained significant insight into one of the mechanisms responsible for this process: multidrug resistance (MDR). Far from being a phenomenon limited to the laboratory, multidrug resistance has been identified in a wide variety of newly diagnosed and recurrent human tumors. A number of compounds can block p-glycoprotein and overcome MDRin vitro andin vivo. Current strategies to block MDR are discussed in this review. Future research in this area will focus on the identification of more selective and potent MDR reversing agents and the development of entirely new approaches to overcoming multidrug resistance such as monoclonal antibodies, immunotoxins, and gene therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Moscow JA, Cowan KH: Multidrug resistance. J Natl Cancer Inst 80:14–20, 1988

    Google Scholar 

  2. Rothenberg M, Ling V: Multidrug resistance: molecular biology and clinical relevance. J Natl Cancer Inst 81:907–913, 1989

    Google Scholar 

  3. Hill BT: Modulation of antitumor drug resistance: experimental laboratory data and results of clinical evaluation. Cancer Treat Rev 17:197–202, 1990

    Google Scholar 

  4. Vendrick CPJ, Bergers JJ, DeJong WH, Steernenberg PA: Resistance to cytostatic drugs at the cellular level. Cancer Chemother Pharmacol 29:413–129, 1992

    Google Scholar 

  5. Kartner N, Ling V: Multidrug resistance in Cancer. Sci Am 260:44–51, 1989

    Google Scholar 

  6. Kessel D, Bottenrill V, Wodinsky I: Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response. Cancer Res 28:938–941, 1968

    Google Scholar 

  7. Dano K: Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 323:466–483, 1973

    Google Scholar 

  8. Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem Biophys Acta 455:152–162, 1976

    Google Scholar 

  9. Safa AR: Photoaffinity labelling of p-glycoprotein in multi-drug resistant cells. Cancer Invest 10:295–305, 1992

    Google Scholar 

  10. Gottesman MM, Pastan I: The multidrug transporter, a double-edged sword. J Biol Chem 263:12163–12166, 1988

    Google Scholar 

  11. Roninson IB: From amplification to function: the case of the MDR1 gene. Mutation Res 276:151–161, 1992

    Google Scholar 

  12. Ling V: P-glycoprotein and resistance to anticancer drugs. Cancer 69:2603–2609, 1992

    Google Scholar 

  13. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingam MC: A retrovirus carrying a MDR1 cDNA confers multidrug resistance and polarized expression of p-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85:4486–4490, 1988

    Google Scholar 

  14. Chaudhary PM, Roninson IB: Expression and activity of p-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66:85–94, 1991

    Google Scholar 

  15. Tatsuta T, Naito M, Oh-hara T, Suguwara I, Tsuruo T: Functional involvement of p glycoprotein in blood-brain barrier. J Biol Chem 267:20383–20391, 1992

    Google Scholar 

  16. Yang CPH, Cohen D, Greenberger LM, Hsu SIH: Differential transport properties of two MDR-gene products are distinguished by progesterone. J Biol Chem 265:10282–10288, 1990

    Google Scholar 

  17. Cordon-Cardo C, O'Brien JP, Casals Det al Multidrugresistance gene (p-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695–698, 1989

    Google Scholar 

  18. Van Kalken CK, Broxterman HJ, Pinedo HM, Feller N, Dekker, Lankelma J, Giaccone G: Cortisol is transported by the multidrug resistance gene product p-glycoprotein. Br J Cancer 67:284–289, 1993

    Google Scholar 

  19. Grosland MP, Brophy NA, Duran GE, Yanhanda AMet.al: Bilirubin: a physiological substrate for the multidrug transporter. Proc Am Assoc Cancer Res 32:426, 1991

    Google Scholar 

  20. Haber DA: Multidrug resistance (MDR1) in leukemia: Is it time to test? Blood 79:295–298, 1992

    Google Scholar 

  21. Chen CJ, Chin JE, Ueda Ket al: Internal duplication and homology with bacterial transport proteins in the mdrl (p-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381–389, 1986

    Google Scholar 

  22. Gros P, Neriah Y, Croop JM, Housman DE: Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323:728–731, 1986

    Google Scholar 

  23. Gerlach JH, Endicott JA, Juranka PF, Henderson G, Sarangi F, Deuchars KL, Ling V: Homology between p-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 324:485–489, 1986

    Google Scholar 

  24. Ueda K, Pastan I, Gottesman MM: Isolation and sequence of the promoter region of the human multidrugresistance (p-glycoprotein) gene. J Bio Chem 262: 17432–17436, 1987

    Google Scholar 

  25. Kohno K, Sato SI, Takano Het al: The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem Biophys Res Comm 165:1415–1421, 1989

    Google Scholar 

  26. Anderson L, Cummings J, Bradshaw T, Smyth JF: The role of protein kinase C and the phophatidylinositor cycle in multidrug resistance in human ovarian cancer cells. Biochem Pharmacol 42:1427–1432, 1991

    Google Scholar 

  27. Jandrig B, Wunderlich V: Membrane transport in multidrug resistance, development, and disease. J Cancer Res Clin Oncol 118:238–239, 1992

    Google Scholar 

  28. Gill DR, Hyde SC, Higgins CF, Valverde MA, Mintenig GM, Sepulveda FV: Separation of drug transport and chloride channel functions of the human multidrug resistance p-glycoprotein. Cell 71:23–32, 1992

    Google Scholar 

  29. Horio M, Gottesman MM, Pastan I: ATP-dependent transport of vinblastine in vesicles from human multidrug resistant cells. Proc Natl Acad Sci USA 85:3580–3584, 1988

    Google Scholar 

  30. Guild BC, Mulligan RC, Gros P, Housman DE: Retroviral transfer of a murine cDNA for multidrug resistance confers pleiotropic drug resistance to cells without prior drug selection. Proc Natl Acad Sci USA 85:1595–1599, 1988

    Google Scholar 

  31. Gupta S, Tsuruo T, Gallapudi S: HIV-induced expression of p-glycoprotein. Sixth International Conference on AIDS, San Francisco, June 1990. A1067

  32. Fojo AT, Whang-Peng J, Gottesman MM, Pastan I: Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 82:7661–7665, 1985

    Google Scholar 

  33. Shen D-W, Fojo A, Chin FE, Roninson IB, Richert N, Pastan I, Gottesman MM: Human multidrug-resistant cell lines: increased mdrl expression can precede gene amplification. Science 232:643–645, 1986

    Google Scholar 

  34. Goldstein LJ, Galski H, Fojo Aet al: Expression of multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116–124, 1989

    Google Scholar 

  35. Dalton WS, Grogan TM, Rybski JAet al: Immuno-histochemical detection and quantitation of p-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood 73:747–752, 1989

    Google Scholar 

  36. Beck WT: Do anti-p-glycoprotein antibodies have a future in the circumvention of multidrug resistance? J Natl Can Inst 83:1364–1366, 1991

    Google Scholar 

  37. Schinkel AH, Roelofs ME, Borst P: Characterization of the human mdr3 p-glycoprotein and its recognition by p-glycoprotein specific monoclonal antibodies. Cancer Research 51:2628–2635, 1991

    Google Scholar 

  38. Battifora H: Specificity of immunohistochemical expression of p-glycoprotein. Human Path 22:506, 1991

    Google Scholar 

  39. Ro J, Sahin A, Ro JY, Firtsche H, Hortobagyi G, Blick M: Immunohistochemical analysis of p-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Human Path 21:787–791, 1990

    Google Scholar 

  40. Weinstein RS, Jakate SM, Doingues JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson IB: Relationship of the expression of the multidrug resistance gene product (p-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51:2720–2726, 1991

    Google Scholar 

  41. Hooberman AL: The use of polymerase chain reaction in clinical oncology. Oncology 6:25–39, 1992

    Google Scholar 

  42. Kang YK, Zhan A, Bryant G, Shives B, Stetler-Stevenson MA, Jaffe E, Wilson W, Chabner BA, Fojo AT, Bates SE: Quantitative PCR analysis of mdr-1 in non-Hodgkin's lymphoma. Proc Am Assoc Cancer Res 34:214, 1993

    Google Scholar 

  43. Herzog CE, Trepel JB, Mickley LA, Bates SE, Fojo AT: Various methods of analysis of mdr-1/p-glycoprotein in human colon cancer cell lines. J Natl Cancer Inst 84:711–716, 1992

    Google Scholar 

  44. Fojo AT, Ueda K, Slamon DJ, Pcplack DG, Gottesman MM, Pastan I: Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265–269, 1987

    Google Scholar 

  45. Rothenberg ML, Mickley LA, Cole DE, Balis FM, Takashi T, Poplack DG, Fojo AT. Expression of the rndr-1/P-170 gene in patients with acute lymphoblastic leukemia. Blood 74:1388–1395, 1989

    Google Scholar 

  46. Campos L, Guyotat D, Archimbaud Eetal: Clinical significance of multidrug resistance p-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79:473–476, 1992

    Google Scholar 

  47. Tiirkainen MI, Syrjala MT, Jansson SE, Krusius T: Flow cytometric analysis of p-glycoprotein in normal and leukemic cells. Ann Hematol 65:124–130, 1992

    Google Scholar 

  48. Kuwazuru Y, Hanada S, Furukawa Tetal: Expression of p-glycoprotein in adult T-cell leukemia cells. Blood 76:2065–2071, 1990

    Google Scholar 

  49. Musto P, Melillo L, Lombardi G, Matera R, Di Giorgio G, Carotenuto M: High risk of early resistance relapse for leukaemic patients with presence of multidrug resistance associated p-glycoprotein positive cells in complete remission. Br J Haem 77:50–53, 1991

    Google Scholar 

  50. Weide R, Dowding C, Paulsen W, Goldman J: The role of the MDR-1/P-170 mechanism in the development of multidrug resistance in chronic myeloid leukemia. Leukemia 4:695–699, 1990

    Google Scholar 

  51. Niehans GA, Jaszcz W, Brunetto Vetal: Immunohistochemical identification of p-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res 52:3768–3775, 1992

    Google Scholar 

  52. Dalton WS, Grogan TM, Meltzer PSetal: Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:415–424, 1989

    Google Scholar 

  53. Sonneveld P, Durie BGM, Lokhorst HM, Frutiger Y, Schoester M, Vela EE: Analysis of multidrug resistance (MDR1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma. Br J Haem 83:63–67, 1993

    Google Scholar 

  54. Danova M, Giordano M, Erba Eetal: Flow cytometric analysis of multidrug analysis of multidrug-resistanceassociated antigen (p-glycoprotein) and DNA ploidy in human colon cancer. J Cancer Res Clin Oncol 118:575–580, 1992

    Google Scholar 

  55. Bates SE, Shieh CY, Tsokos M: Expression ofmdr-1/p- glycoprotein in human neuroblastoma. Am J Path 139:305–315, 1991

    Google Scholar 

  56. Chan HSL, Haddad G, Thonier PSetal: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. New Engl J Med 325:1608–1614, 1991

    Google Scholar 

  57. Favrot M, Combaret V, Goillot E, Wagner JP, Bouffet E, Mazingue F, Thyss A, Bordigoni P, Delsol G, Bailly C, Fontaniere B, Philip T: Expression of p-glycoprotein restricted to normal cells in neuroblastoma biopsies. Br J Cancer 64:233–238, 1991

    Google Scholar 

  58. Toffoli G, Frastaci S, Tumiotto L, Talamini R, Gherlinzoni F, Picci P, Boiocchi M: Expression of MDR1 and GST-o in human soft tissue sarcomas: relation to drug resistance and biological aggressiveness. Ann Oncol 3:63–69, 1992

    Google Scholar 

  59. Schneider J, Efferth T, Centeno MM, Mattern J, Rodriguez-Escudero FJ, Volm M: High rate of expression of multidrug resistance associated p-glycoprotein human endometrial carcinoma and normal endometrial tissue. Eur J Cancer 29A:554–558, 1993

    Google Scholar 

  60. Robey-Cafferty SS, Bruner JM, Cafferty LL: P-glycoprotein expression in gastroesophageal adenocarcinomas, their metastases, and surrounding mucosa: a mapping study. Modern Path 4:694–697, 1991

    Google Scholar 

  61. Saclarides TJ, Jakate SM, Coon JS. Bhattacharyya AK, Dominguez JM, Szeluga DJ, Weinstein RS: Variable expression of p-glycoprotein in normal, inflamed, and dysplastic areas in ulcerative colitis. Dis Colon Rectum 35:747–752, 1992

    Google Scholar 

  62. Merkel DE, Fuqua SAW, Tandon AKetal: Electrophoretic analysis of 248 clinical breast cancer specimens for p-glycoprotein overexpression or gene amplification. J Clin Oncol 7:1129–1136, 1989

    Google Scholar 

  63. Lizard G, Roignot P, Dussere-Guion L, Morlevat F, Michiels-Marzais D, Ferry N, Tremeaux JC: Characterization of seven kidney tumors by flow cytometry; analysis of cell cycle, DNA content and p-glycoprotein expression. Eur Urol 2(suppl l):39–42, 1992

    Google Scholar 

  64. Fuchs B, Ostmeier H, Suter L: P-glycoprotein expression in malignant melanoma. J Cancer Res Clin Oncol 117:168–171, 1991

    Google Scholar 

  65. Cairo MS, Plunkett JM, Gillan E, Weinthal J, Knoppel EC, Sender L: A novel preparative and purging regimen employing verapamil to modulate multiple drug resistance during autologous bone marrow transplant in acute lymphoblastic leukemia: a pilot study. Proc Am Assoc Cancer Res 33:199, 1992

    Google Scholar 

  66. Ramu A, Ramu N: Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemother Pharmacol 30:165–173, 1992

    Google Scholar 

  67. Nalto M, Yusa K, Takashi T: Steroid hormones inhibit binding of vinca alkaloid to multidrug resistance related to p-glycoprotein. Biochem Biophys Res Comm 158:1066–1071, 1989

    Google Scholar 

  68. Cornwell MM, Gottesman MM, Pastan I: Increased vinblastine binding to membrane vesicles from multidrug-resistant KB cells. J Biol Chem 261:7921–7928, 1986

    Google Scholar 

  69. Cornwell MM, Pastan I, Gottesman MM: Certain calcium blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to p-glycoprotein. J Biol Chem 262:2166–2170, 1987

    Google Scholar 

  70. Woodcock DM, Linsenmeyer ME, Chojnowski G, Kriegler AB, Nink V, Webster LK, Sawyer WH: Reversal of multidrug resistance by surfactants. Br J Cancer 66:62–68, 1992

    Google Scholar 

  71. Cuvier C, Roblot-Treupel L, Millot JMetal: Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem Pharmacol 44:509–517, 1992

    Google Scholar 

  72. Chervinsky DS, Brecher ML, Hoelcle MJ: Cremophor-EL enhances taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line. Anticancer Res 13:93–96, 1993

    Google Scholar 

  73. Fleming GF, Amato JM, Agresti M, Safa AR: Megestrol acetate reverses multidrug resistance and interacts with p-glycoprotein. Cancer Chemother Pharmacol 29:445–449, 1992

    Google Scholar 

  74. DeGregorio MW, Ford JM, Benz CC, Wiebe VJ: Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. J Clin Oncol 7:1359–1364, 1989

    Google Scholar 

  75. Kellen JA, George E, Ling V: Decreased p-glycoprotein in a tamoxifen tolerant breast carcinoma model. Anticancer Res 11:1243–1244, 1991

    Google Scholar 

  76. Chatterjee M, Harris AL: Enhancement of adriamycin cytotoxicity in a multidrug resistant Chinese hamster ovary subline, CHO-Adrr, by toremifene and its modulation by alpha 1 acid glycoprotein. Eur J Cancer 26:432–436, 1990

    Google Scholar 

  77. Speeg KV, Maldonado AL, Liaci J, Muirhead D: Effect of cyclosporine on colchicine secretion by a liver canalicular transporter studiedin vivo. Hepatology 15:899–903, 1992

    Google Scholar 

  78. Speeg KV, Maldonado AL, Liaci L, Muirhead D: Effect of cyclospirine on colchicine secretion by the kidney multidrug transporter studiedin vivo. J Pharm Exp Ther 261:50–55, 1992

    Google Scholar 

  79. Boesch D, Gaveriaux C, Jachez B:In vivo circumvention of p-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51:4226–4233, 1991

    Google Scholar 

  80. Lenhart M, Dalton WS, Roe D: Synergistic inhibition by verapamil and quinine of p-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood 77:348–354, 1991

    Google Scholar 

  81. Mickisch GH, Merlino GT, Aiken PMetal: New potent verapamil derivatives that reverse multidrug resistance in human renal carcinoma cells and in transgenic mice expressing the human MDR1 gene. J Urol 146:447–453, 1991

    Google Scholar 

  82. Mickisch GH, Merlino GT, Galski H, Gottesman MM, Pastan I: Transgenic mice that express the human multidrug resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA 88:547, 1991

    Google Scholar 

  83. Ozols RF, Cunnion RE, Klecker RW, Hamilton TC, Ostchega Y, Parrillo JE, Young RC: Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer. J Clin Oncol 5:641–647, 1987

    Google Scholar 

  84. Salmon SE, Dalton WS, Grogan TMetal: Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78:44–50, 1991

    Google Scholar 

  85. Benson AB, Trump DL, Koeller JMetal: Phase I study of vinblastine and verapamil given by concurrent IV infusion. Cancer Treat Rep 69:795–799, 1985

    Google Scholar 

  86. Pennock GD, Dalton WS, Roeske WRetal: Systemic toxic effects associated with high dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 83:105–111, 1991

    Google Scholar 

  87. Cairo MS, Siegel S, Anas N, Sender L: Clinical trial of continuous infusion of verapamil, bolus vinblastine and continuous infusion VP-16 in drug-resistant pediatric tumors. Cancer Res 49:1063–1066, 1989

    Google Scholar 

  88. Presant CA, Kennedy PS, Wiseman Cetal: Verapamil reversal of clinical doxorubicin resistance in human cancer. Am J Clin Oncol 9:355–357, 1986

    Google Scholar 

  89. Bissett D, Kerr DJ, Cassidy Jetal: Phase I trial and pharmacokinetic study of D-verapamil and doxorubicin. Br J Cancer 64:1168–1171, 1991

    Google Scholar 

  90. Bessho F, Kinumaki H, Kobayashi Metal: Treatment of children with refractory acute lymphocytic leukemia with vincristine and diltiazem. Med Ped Oncol 13:199–202, 1985

    Google Scholar 

  91. Solary E, Caillot D, Chauffert B, Casanovas RO, Duman M, Maynadie M, Guy H: Feasibility of using quinine, a potential multidrug resistance-reversing agent in combination with mitoxanthrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 10:1730–1736, 1992

    Google Scholar 

  92. Miller RL, Burkowski RM, Budd GTetal: Clinical modulation of doxorubicin resistance by the calmodulin inhibitor, trifluoperazine: a phase I–II trial. J Clin Oncol 6:880–888, 1988

    Google Scholar 

  93. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W: Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11:1652–1660, 1993

    Google Scholar 

  94. Yahanda AM, Adler KM, Fisher GAetal: Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 10:1624–1634, 1992

    Google Scholar 

  95. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI: Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635–1642, 1992

    Google Scholar 

  96. Maenpaa J, Sipila P, Kangas L, Karnani P, Gronroos M: Chemosensitizing effect of an antiestrogen, on ovarian cancer. Gynecologic Oncol 46:292–297, 1992

    Google Scholar 

  97. Acland SP, Ratain MJ, Vogelzang NJetal: Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin. Clin Pharmacol Ther 45:340–347, 1989

    Google Scholar 

  98. Bennis S, Robert J, Nemati F, Dubernet C, Couvreur P: Enhanced toxicity of doxorubicin encapsulated in polyisohexycyanoacrylate nanospheres against multidrug-resistant tumoral cells in culture. Proc Am Assoc Cancer Res 33:476, 1992

    Google Scholar 

  99. Thierry AR, Dritschilo A, Rahman A: Effect of liposomes on p-glycoprotein function in multidrug resistant cells. Biochem Biophys Res Comm 187:1098–1105, 1992

    Google Scholar 

  100. Saltz L, O'Brien J, Kemeny N, Murphy B, Niedzwiecki D, Tong W, Lin S, Kelsen D, Bertino J: Phase I study of intrahepatic verapamil and doxorubicin: regional therapy to overcome multidrug resistance. Proc Am Soc Clin Oncol 11:118, 1992

    Google Scholar 

  101. O'Shaughnessy JA: Personal communication, 1993

  102. Baer MR, Bloomfield CD: Multidrug resistance in acute myeloid leukemia. J Natl Cancer Inst 83:663–665, 1991

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patel, N.H., Rothenberg, M.L. Multidrug resistance in cancer chemotherapy. Invest New Drugs 12, 1–13 (1994). https://doi.org/10.1007/BF00873229

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00873229

Key words

Navigation